After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...